Quillen, Esq.Foley Hoag LLPSeaport West155 Seaport BoulevardBoston, Massachusetts 02110(617)832-1000Stuart Bressman, Esq.Proskauer Rose LLPEleven Times SquareNew York, NY 10036(212) 969-3000Approximate date of commencement of proposed sale to the public:As soon as practicable after this Registration Statement is declared effective.If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
subject to the underwriters’ option to purchase additional shares.(2)Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price of the securities registered hereunder.(3)Previously paid.The Registrant hereby
securities in any state where the offer or sale is not permitted.Subject to completion, dated March 28, 2018PROSPECTUS10,000,000 SharesCommon Stock$             per share•  Zosano Pharma Corporation is offering 10,000,000 shares of its common
2018.BTIGThe date of this prospectus is                     , 2018.Table of ContentsTABLE OF CONTENTSProspectus Summary1Risk Factors12Cautionary Note Regarding Forward-looking Statements15Industry and Market Data17Use of Proceeds18Market Price of Our Common Stock19Dividend Policy20Capitalization21Dilution23Business25Certain Relationships and Related Person Transactions39Principal Stockholders41Description of Capital Stock44Underwriting47Legal Matters55Experts55Incorporation by Reference56Where You Can Find More Information57You should rely only on the information contained in this prospectus, including the information incorporated by reference herein, and any related free writing prospectus that we may provide you in
exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading “Where You Can Find More Information.”For investors outside the United States: neither we nor any of the underwriters have taken any action to permit a public offering of the shares of our
pursuant to the terms of the LPC Purchase Agreement.8Table of ContentsExcept as otherwise noted, all information in this prospectus:•assumes no additional shares will be issued to LPC pursuant to the terms of the LPC Purchase Agreement;•assumes no exercise of outstanding options or warrants described above;•assumes no exercise by the underwriters of their over-allotment option; and•gives effect to a 1-for-20 reverse split of our common stock which became effective on January 25, 2018.Two of our directors, including our chief executive officer, have indicated an interest in purchasing shares in this offering at the public offering
incorporated by reference in this prospectus from our Annual Report on Form10-Kfor the fiscal year ended December 31, 2017.The as adjusted balance sheet data as of December 31, 2017 reflects receipt of the estimated net proceeds from the sale of 10,000,000 shares of common stock at an assumed public offering price of
Adjusted(1)Selected Balance Sheet Data:Cash and cash equivalents$11,651$57,359Working capital2,93648,644Total assets18,00063,708Secured promissory note (including accrued interest), net of issuance costs, current portion6,6876,687Accumulated deficit(225,874)(225,874)Total stockholders’ equity7,04852,756(1)As adjusted to reflect the receipt of the estimated net proceeds of $45.7 million from the sale of 10,000,000 shares of common stock, at the
license and collaboration agreements, as well as the exercise of options and warrants outstanding, following this offering, will dilute your ownership interests and may adversely affect the future market price of our common stock.The net proceeds from this offering and our existing cash and cash equivalents will not be sufficient to fund all of the efforts that
stock could be dilutive to shareholders if they do not invest in future offerings, and our participation in a debt financing or license or collaboration agreement will also be dilutive to shareholders.12Table of ContentsIn addition, we have a significant number of options and warrants to purchase shares of our common
199,524 shares of our common stock and there-saleof 197,941 of these shares is registered under the Securities Act of 1933, as amended, or the Securities Act, on a registration statement onForm S-3.These shares registered onForm S-3,once issued upon exercise of the warrants, will be able to be freely sold in the public market, subject to thelock-upagreements described above, to the extent applicable.
The market price for our common stock may be influenced by many factors, including:•announcements relating to development, regulatory approvals or commercialization of our product candidates or those of competitors;•results of clinical trials of our product candidates or those of our competitors;•announcements by us or our competitors of significant strategic partnerships or collaborations or terminations of such arrangements;•actual or anticipated variations in our operating results;•changes in financial estimates by us or by any securities analysts who might cover our stock;•conditions or trends in our industry;•changes in laws or other regulatory actions affecting us or our industry;•stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;•announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;•capital commitments;•investors’ general perception of our company and our business;•disputes concerning our intellectual property or other proprietary rights;•recruitment or departure of key personnel; and•sales of our common stock, including sales by our directors and officers or specific stockholders.In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the
products;•our manufacturing capabilities and strategy;•our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;•our intellectual property position and our ability to obtain and maintain intellectual property protection for our product candidates;•our expectations regarding competition;•the anticipated trends and challenges in our business and the markets in which we operate;•the scope, progress, expansion, and costs of developing and commercializing our product candidates;•the size and growth of the potential markets for our product candidates and the ability to serve those markets;•the rate and degree of market acceptance of any of our product candidates;•our ability to establish and maintain development partnerships;•our ability to attract or retain key personnel;•our expectations regarding federal, state and foreign regulatory requirements; and•regulatory developments in the United States and foreign countries.These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject